All In Biotech

Drug Trial Radar · NCT04469920

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis

Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Jul 16, 2020

Primary completion

Mar 21, 2022

Study completion Mar 21, 2022

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function

Conditions

  • Hepatic Impairment

Interventions

  • Saroglitazar Magnesium 2 mgDrug

    1 tablet, single dose at Day 1

  • Saroglitazar Magnesium 4 mgDrug

    1 tablet, single dose at Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC from time zero to infinity (AUC0-∞)Time frame: Before dosing on Day 1 through Day 7
  2. AUC from time zero to the last quantifiable concentration (AUC0-t)Time frame: Before dosing on Day 1 through Day 7
  3. CmaxTime frame: Before dosing on Day 1 through Day 7
  4. TmaxTime frame: Before dosing on Day 1 through Day 7
  5. t1/2Time frame: Before dosing on Day 1 through Day 7
  6. CL/FTime frame: Before dosing on Day 1 through Day 7
  7. Vz/FTime frame: Before dosing on Day 1 through Day 7

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • American Research Corporation at Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.